Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
RNA Stock Chart & Stats
$72.51
-$0.39(-1.27%)
At close: 4:00 PM EST
$72.51
-$0.39(-1.27%)
Day’s Range― - ―
52-Week Range$21.51 - $72.70
Previous CloseN/A
Volume185.29K
Average Volume (3M)1.95M
Market Cap
$10.93B
Enterprise Value$10.63B
Total Cash (Recent Filing)$1.88B
Total Debt (Recent Filing)$49.97M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 03, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding150,749,570
10 Day Avg. Volume2,017,571
30 Day Avg. Volume1,951,222
Financial Highlights & Ratios
PEG Ratio14.65
Price to Book (P/B)2.28
Price to Sales (P/S)297.77
P/FCF Ratio-10.54
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue509.17
Enterprise Value/Gross Profit-90.62
Enterprise Value/Ebitda-17.87
Forecast
1Y Price Target
$74.42Price Target Upside2.63% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)-4.92
Revenue Forecast (FY)$18.79M
Bulls Say, Bears Say
Bulls Say
Acquisition CertaintyNovartis' definitive agreement to acquire Avidity Biosciences for $72 per share in cash creates a clear value realization path for Avidity shareholders, subject to customary regulatory and shareholder approvals.
SpinCo CapitalizationPlanned spin-out of the early-stage precision cardiology programs into a SpinCo capitalized with $270 million in cash positions the new company to fund development and attract independent investors.
Strategic Pipeline FitNovartis' acquisition secures Avidity's neuromuscular assets and AOC platform, leveraging Novartis' neuroscience expertise to accelerate late-stage programs and commercialization potential.
Bears Say
Analyst Downgrades And Valuation PressureAnalyst downgrades and price target reductions to levels near the announced takeout price reflect limited upside without a competing bidder and raise the risk of valuation compression for the stock.
Asset Base ReductionSeparation and spin-out of preclinical cardiac and collaboration assets will shrink Avidity's retained asset base, potentially reducing the company’s long-term standalone growth profile.
Regulatory And Clinical RiskDependence on successful clinical outcomes and regulatory approvals for key programs such as del-desiran, del-brax and del-zota creates material execution risk that could materially impact valuation if trials fail.
Avidity Biosciences News
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $72.70 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Avidity Biosciences Inc’s market cap is $10.93B.
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Mar 03, 2026 which is in 43 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Nov 10, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$1.085 by -$0.185.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -1.24.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 150,749,570 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$1.27 in its last earnings report, missing expectations of -$1.085. Following the earnings report the stock price went up 1.231%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Currently, no hedge funds are holding shares in RNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avidity Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$74.42 (2.63% Upside)
$74.42 (2.63% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
156.30%
12-Months-Change
Fundamentals
Return on Equity
-32.44%
Trailing 12-Months
Asset Growth
30.07%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
RNA Stock 12 Month Forecast
Average Price Target
$74.42
▲(2.63% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
29.14% Mutual Funds
0.09% Other Institutional Investors
56.21% Public Companies and
Individual Investors